Phaseline

Targets › GCK

GCK (Hexokinase-4): drug programs, companies and trials

5 programs from 5 companies in 15 trials: 11 Phase 3, 3 Phase 1, 1 Phase 2; Metabolic and endocrine, Cardiovascular, Genitourinary; next expected readout Nov 2026.

Catalyzes the phosphorylation of hexose, such as D-glucose, D-fructose and D-mannose, to hexose 6-phosphate (D-glucose 6-phosphate, D-fructose 6-phosphate and D-mannose 6-phosphate, respectively). Compared to other hexokinases, has a weak affinity for D-glucose, and is effective only when glucose is abundant (By similarity). (UniProt, P35557)

Open in Phaseline: the race on GCK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaElecoglipron
Dipeptidyl peptidase-4 (DPP-4) inhibitor
DPP4, GCK, GCGRPhase 3Obesity; Type 2 Diabetes Mellitus; Weight Management; Heart Failure With Preserved Ejection Fraction (HFpEF) …Nov 2026
vTv TherapeuticsCadisegliatin
Glucokinase activator
GCKPhase 3Diabetes Mellitus, Type 1Apr 2027
University of Alabama at BirminghamDorzagliatin
Glucokinase activator
GCKPhase 3Type 2 Diabetes–
Chinese University of Hong KongDorzagliatin
Allosteric glucokinase activator
GCKPhase 2Diabetes MellitusDec 2026
Michael R. Rickels, MD, MSDorzagliatin
Glucokinase activator
GCKPhase 1Pancreatic InsufficiencyJul 2027

Conditions

Type 2 Diabetes Mellitus (5) Healthy Participants (2) Obesity (1) Weight Management (1) Heart Failure With Preserved Ejection Fraction (HFpEF) (1) Chronic Kidney Disease (1) Type 2 Diabetes (1) Diabetes Mellitus (1) Pancreatic Insufficiency (1) Diabetes Mellitus, Type 1 (1)

Modalities

small molecule (4), mixed (1)

Companies

AstraZeneca (1) University of Alabama at Birmingham (1) Chinese University of Hong Kong (1) Michael R. Rickels, MD, MS (1) vTv Therapeutics (1)

Related targets

DPP4 (1) GCGR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.